Neue Novavax: Anstieg nach 1:20 Re-Split
Seite 281 von 354 Neuester Beitrag: 10.06.24 19:00 | ||||
Eröffnet am: | 16.08.19 19:30 | von: moneywork4. | Anzahl Beiträge: | 9.84 |
Neuester Beitrag: | 10.06.24 19:00 | von: Unicorn71 | Leser gesamt: | 2.282.869 |
Forum: | Hot-Stocks | Leser heute: | 853 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 279 | 280 | | 282 | 283 | ... 354 > |
Aber bitte nicht weitersagen weil allein Matrix-M mittlerweile vermutlich sonst mehr wert ist als komplett Novavax wenn man streng nach aktuellem Börsenkurs geht ;) schräge Börsenwelt halt manchmal, macht man aber nix dran..... Ein großer Mitbewerber dessen Adjuvanz nach meinen Recherchen nichtmal 50% so effizient macht z.B. nichts anderes als nur Adjuvanz und was soll man sagen? Auch mehr wert als Novavax Komplettpacket momentan. Wenn man jetzt noch die Milliarde free Cash und die Milliarden an unantastbaren und absolut wasserdichten festen Aufträgen hinzurechnet kann man sich nur noch an den Kopf greifen.
Egal.......
Naja, die Hoffnung stirbt zuletzt, und ein BO bzw. übernahme für 150 Dollar hört sich für mixh in der jetzigen Situation auch nicht schlecht an, aber auch nur, weil Novavax mein persönliches Wirecard ist.
https://finance.yahoo.com/m/...c73e68/valneva-says-the-ema-wants.html
Immerhin ca. +%300, nehmen wir doch gerne, oder?
https://m.thefly.com/search/NVAX
Finde es ganz schwer zu prognostizieren...
...Prashant Khadayate, Pharma Analyst at GlobalData, comments: “GlobalData consensus forecast predicts that Takeda could generate sales of US$943m through supplying Nuvaxovid in Japan in 2022.”
Takeda has an agreement with the Japanese government to supply 150 million doses of Nuvaxovid. Similarly, Novavax has partnered with leading local players within Asia such as Serum Institute of India for India, Indonesia and the Philippines, and SK bioscience for South Korea.
Japan is still reporting a 7-day average of more than 40,000 cases per day. Hence, COVID-19 is still highly unpredictable though most of the people are now infected with mild symptoms of COVID-19 infection.
Khadayate concludes: “Forging strong local partnerships can provide Novavax to scale up manufacturing and commercialization abilities to fulfill government orders from various countries. In addition, Japanese approval helps fulfill Novavax existing vaccine supply contracts with the Japanese government. However, based on its local reputation, Takeda can play a key role in getting government supply orders for Nuvaxovid in the future.”
https://www.globaldata.com/media/pharma/...pand-asia-says-globaldata/
Muss jede/r selbst wissen....
...Poonawalla said SII is geared up for the rollout of its second Covid vaccine Covavax for children for 12 years and above in a week or two, subject to clearance from the National Technical Advisory Group on Immunisation (NTAGI) committee.
“It’s (child vaccination) not picked up as much. And the reason is partly because our vaccine (Covavax) has not been allowed to go into the programme yet… everyone has been waiting for Covavax, which is a vaccine we’re selling in Europe and Australia. In a week or two, when the government decides to allow that in the program on the Cowin app, I think we’ll see a surge in uptake,” he said.
https://dellyranks.com/...munity-than-mrna-jabs-says-adar-poonawalla/
...Government panel National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, news agency ANI reported citing sources.
Earlier, Centre on Thursday had notified that a decision regarding vaccination of children will be taken on the basis of the recommendation by NTAGI on Friday. This comes after Prime Minister Narendra Modi stressed vaccination for all eligible children at the earliest with “special campaigns" in schools is a priority for the Government.
https://www.businesstoday.in/coronavirus/story/...t-331844-2022-04-29